Who
Amy E. McKee
Director
Company insider
Files Form 4 as: Director, BioCryst Pharmaceuticals.
In numbers
- Trades disclosed
- 24
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $255K
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 20 Sep 2021
- Last trade
- 31 Aug 2026
- Last filed
- 2 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Aug 2026filed 2 Sep 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $6,247644 at $9.70 | filing |
| 31 Aug 2026filed 2 Sep 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $6,247644 at $9.70 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —15,294 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,540 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,540 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —15,294 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $5,622631 at $8.91 | filing |
| 29 May 2026filed 2 Jun 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $5,622631 at $8.91 | filing |
| 18 May 2026filed 19 May 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $100K11,180 at $8.97 | filing |
| 18 May 2026filed 19 May 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $100K11,180 at $8.97 | filing |
| 27 Feb 2026filed 3 Mar 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $5,618642 at $8.75 | filing |
| 27 Feb 2026filed 3 Mar 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $5,618642 at $8.75 | filing |
| 28 Nov 2025filed 2 Dec 2025 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $5,622783 at $7.18 | filing |
| 29 Aug 2025filed 3 Sep 2025 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $5,618676 at $8.31 | filing |
| 12 Jun 2025filed 16 Jun 2025 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,181 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 24 Jun 2024filed 25 Jun 2024 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $54K8,600 at $6.32 | filing |
| 12 Jun 2024filed 14 Jun 2024 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —49,933 at $0.00 | filing |
| 12 Jun 2024filed 14 Jun 2024 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —6,820 at $0.00 | filing |
| 13 Jun 2023filed 15 Jun 2023 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,072 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.